Description
Trade name:
Yaz
Compound:
24 light pink tablets contain:
Ethinyl estradiol 0.02 mg
Drospirenone 3 mg
4 white tablets do not contain active ingredients.
Excipients: lactose monohydrate, corn starch, magnesium stearate.
Properties:
Combined hormonal contraceptive drug with antimineralocorticoid and antiandrogenic action.
The contraceptive effect of combined oral contraceptives (COCs) is based on the interaction of various factors, the most important of which are suppression of ovulation and changes in the endometrium.
When used correctly, the Pearl Index (the number of pregnancies per 100 women per year) is less than 1. If tablets are missed or used incorrectly, the Pearl Index may increase.
Drospirenone, contained in the drug, has an antimineralocorticoid effect. It prevents weight gain and edema associated with estrogen-induced fluid retention, which ensures good tolerability of the drug. Drospirenone has a positive effect on premenstrual syndrome (PMS). The clinical effectiveness of the drug in alleviating the symptoms of severe PMS, such as severe psychoemotional disorders, breast engorgement, headache, muscle and joint pain, weight gain and other symptoms associated with the menstrual cycle, has been demonstrated.
Drospirenone also has antiandrogenic activity and helps reduce acne, oily skin and hair (seborrhea).
Indications:
contraception;
contraception and treatment of moderate acne vulgaris;
contraception and treatment of severe premenstrual syndrome.
Method of administration and dosage:
The tablets should be taken in the order shown by the arrows on the pack, at about the same time each day, with a little water. There is no tablet-free interval. One tablet should be taken 1 day consecutively for 28 days. Each subsequent pack should be started on the day after the last tablet in the previous pack. Withdrawal bleeding usually starts 2-3 days after starting the hormone-free (white) tablets and may not have finished before the next pack is started. Each new pack should always be started on the same day of the week, and withdrawal bleeding will occur on about the same days each month.
Start taking Yaz:
If no hormonal contraceptive was used in the previous month,
Yaz should be started on day 1 of the menstrual cycle (i.e. day 1 of menstrual bleeding). You should take the tablet marked with the corresponding day of the week. Then you should take the tablets in order. It is permissible to start taking on days 2-5 of the menstrual cycle, but in this case it is recommended to additionally use a barrier method of contraception during the first 7 days of taking the tablets from the first package.
Taking missed pills
If the delay in taking the drug is less than 12 hours, contraceptive protection is not reduced. The woman should take the tablet as soon as possible, the next tablet is taken at the usual time.
If you are more than 12 hours late taking the pill, contraceptive protection is reduced. The more pills you miss, and the closer the missed pill is to the 7-day break in taking pills, the greater the chance of pregnancy.
It is important to remember:
Taking the drug should never be interrupted for more than 7 days.
7 days of continuous tablet intake is required to achieve adequate suppression of the hypothalamic-pituitary-ovarian axis.
Contraindications:
– thrombosis (venous and arterial) and thromboembolism (including deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke), cerebrovascular disorders – currently or in history;
– migraine with focal neurological symptoms currently or in history;
– diabetes mellitus with vascular complications;
-pancreatitis with severe hypertriglyceridemia at present or in the anamnesis;
– liver failure and severe liver disease (until normalization of liver function tests);
– severe or acute renal failure;
– vaginal bleeding of unknown origin;
-pregnancy or suspicion of it;
– breastfeeding period;
Precautions:
The increased risk of thromboembolism in the postpartum period should be taken into account.
Peripheral circulatory disorders may also be observed in diabetes mellitus, systemic lupus erythematosus, hemolytic uremic syndrome, chronic inflammatory bowel diseases (Crohn’s disease or ulcerative colitis), and sickle cell anemia.
An increase in the frequency and severity of migraine during the use of COCs (which may precede cerebrovascular accidents) is a reason for immediate discontinuation of these drugs.
Side effects:
Headache, lethargy, drowsiness, nausea, pain in the mammary glands, irregular uterine bleeding, bleeding from the genital tract of unspecified origin.
Storage method:
At a temperature not exceeding 30 degrees. In a dry place.
